The current status of clinical proteomics and the use of MRM and MRM3 for biomarker validation

The transfer of biomarkers from the discovery field to clinical use is still, despite progress, on a road filled with pitfalls. Since the emergence of proteomics, thousands of putative biomarkers have been published, often with overlapping diagnostic capacities. The strengthening of the robustness of discovery technologies, particularly in mass spectrometry, has been followed by intense discussions on establishing well-defined evaluation procedures for the identified targets to ultimately allow the clinical validation and then the clinical use of some of these biomarkers. Some of the obstacles to the evaluation process have been the lack of the availability of quick and easy-to-develop, easy-to-use, robust, specific and sensitive alternative quantitative methods when immunoaffinity-based tests are unavailable. Multiple reaction monitoring (MRM; also called selected reaction monitoring) is currently proving its capabilities as a complementary or alternative technique to ELISA for large biomarker panel evaluation. Here, we present how MRM3 can overcome the lack of specificity and sensitivity often encountered by MRM when tracking minor proteins diluted by complex biological matrices.

[1]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[2]  Douglas A Jeffery,et al.  "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. , 2008, Journal of proteome research.

[3]  Mehdi Mesri,et al.  Restructuring proteomics through verification. , 2010, Biomarkers in medicine.

[4]  Leimin Fan,et al.  Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. , 2007, Journal of pharmaceutical and biomedical analysis.

[5]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Craig Lawless,et al.  Global absolute quantification of a proteome: Challenges in the deployment of a QconCAT strategy , 2011, Proteomics.

[7]  Henry Rodriguez,et al.  The journey to regulation of protein-based multiplex quantitative assays. , 2011, Clinical chemistry.

[8]  E. Fung,et al.  A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. , 2010, Clinical chemistry.

[9]  Amanda G. Paulovich,et al.  An Automated and Multiplexed Method for High Throughput Peptide Immunoaffinity Enrichment and Multiple Reaction Monitoring Mass Spectrometry-based Quantification of Protein Biomarkers* , 2009, Molecular & Cellular Proteomics.

[10]  Dafang Zhong,et al.  Applications of liquid chromatography-tandem mass spectrometry in drug and biomedical analyses. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[11]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[12]  D R Mani,et al.  Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. , 2009, Clinical chemistry.

[13]  Andrew N Hoofnagle,et al.  Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. , 2008, Clinical chemistry.

[14]  Christoph H Borchers,et al.  Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma* , 2009, Molecular & Cellular Proteomics.

[15]  K. Kinzler,et al.  Mutant proteins as cancer-specific biomarkers , 2011, Proceedings of the National Academy of Sciences.

[16]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.

[17]  N. Anderson,et al.  The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. , 2010, Clinical chemistry.

[18]  L Liotta,et al.  Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. , 2010, Journal of proteome research.

[19]  R. Aebersold,et al.  mProphet: automated data processing and statistical validation for large-scale SRM experiments , 2011, Nature Methods.

[20]  Wilhelm Schänzer,et al.  Current role of LC-MS(/MS) in doping control , 2007, Analytical and bioanalytical chemistry.

[21]  Hanno Steen,et al.  Design and validation of a high-throughput matrix-assisted laser desorption ionization time-of-flight mass spectrometry method for quantification of hepcidin in human plasma. , 2011, Analytical chemistry.

[22]  Frank T Peters,et al.  Recent advances of liquid chromatography-(tandem) mass spectrometry in clinical and forensic toxicology. , 2011, Clinical biochemistry.

[23]  Zheng Ouyang,et al.  A strategy for metabolite identification using triple-quadrupole mass spectrometry with enhanced resolution and accurate mass capability. , 2003, Rapid communications in mass spectrometry : RCM.

[24]  Linfeng Wu,et al.  Absolute Quantification of Multisite Phosphorylation by Selective Reaction Monitoring Mass Spectrometry , 2006, Molecular & Cellular Proteomics.

[25]  C. Vogel,et al.  Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma. , 1972, Cancer research.

[26]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[27]  Mira Petrovic,et al.  Recent trends in the liquid chromatography-mass spectrometry analysis of organic contaminants in environmental samples. , 2010, Journal of chromatography. A.

[28]  Alex van Belkum,et al.  Biomedical Mass Spectrometry in Today's and Tomorrow's Clinical Microbiology Laboratories , 2012, Journal of Clinical Microbiology.

[29]  Tatsuya Shinoda,et al.  Noncompetitive detection of low molecular weight peptides by open sandwich immunoassay. , 2007, Analytical chemistry.

[30]  A. Chinnaiyan,et al.  Development of selected reaction monitoring‐MS methodology to measure peptide biomarkers in prostate cancer , 2010, Proteomics.

[31]  D R Mani,et al.  Interlaboratory Evaluation of Automated, Multiplexed Peptide Immunoaffinity Enrichment Coupled to Multiple Reaction Monitoring Mass Spectrometry for Quantifying Proteins in Plasma* , 2011, Molecular & Cellular Proteomics.

[32]  C. Lenz,et al.  Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. , 2009, Analytical chemistry.

[33]  Vincenzo Pucci,et al.  Enhanced mass resolution method development, validation and assay application to support preclinical studies of a new drug candidate. , 2006, Rapid communications in mass spectrometry : RCM.

[34]  Pingbo Zhang,et al.  Multiplex assays for biomarker research and clinical application: Translational science coming of age , 2010, Proteomics. Clinical applications.

[35]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[36]  Christopher R Kinsinger,et al.  Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. , 2010, Clinical chemistry.

[37]  T. Shaler,et al.  Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. , 2006, Analytical chemistry.

[38]  Zhaojing Meng,et al.  Targeted mass spectrometry approaches for protein biomarker verification. , 2011, Journal of proteomics.

[39]  R. Aebersold,et al.  Increased Selectivity, Analytical Precision, and Throughput in Targeted Proteomics , 2010, Molecular & Cellular Proteomics.

[40]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[41]  Andrew N Hoofnagle,et al.  Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. , 2010, Clinical chemistry.

[42]  Pei Wang,et al.  A targeted proteomics–based pipeline for verification of biomarkers in plasma , 2011, Nature Biotechnology.

[43]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[44]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[45]  K. Schneider,et al.  Quantitative electrospray LC-MS and LC-MS/MS in biomedicine. , 1998, Journal of pharmaceutical and biomedical analysis.

[46]  E. Diamandis,et al.  The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. , 2010, Clinical chemistry.

[47]  A. Salvador,et al.  Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests , 2009, Molecular & Cellular Proteomics.

[48]  R. Aebersold,et al.  High Sensitivity Detection of Plasma Proteins by Multiple Reaction Monitoring of N-Glycosites*S , 2007, Molecular & Cellular Proteomics.

[49]  Jérôme Garin,et al.  Protein Standard Absolute Quantification (PSAQ) for improved investigation of staphylococcal food poisoning outbreaks , 2008, Proteomics.

[50]  Christoph H Borchers,et al.  Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension , 2010, Journal of the American Society for Mass Spectrometry.

[51]  Paul M Southworth,et al.  A mass spectrometric strategy for absolute quantification of Plasmodium falciparum proteins of low abundance , 2011, Malaria Journal.

[52]  Christoph H Borchers,et al.  Dietary patterns and ethnicity are associated with distinct plasma proteomic groups. , 2012, The American journal of clinical nutrition.

[53]  R. Beynon,et al.  Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides , 2005, Nature Methods.

[54]  Christoph H Borchers,et al.  A Human Proteome Detection and Quantitation Project* , 2009, Molecular & Cellular Proteomics.

[55]  Christopher R Kinsinger,et al.  Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. , 2010, Clinical chemistry.

[56]  T. Klaassen,et al.  Validated quantitation method for a peptide in rat serum using liquid chromatography/high-field asymmetric waveform ion mobility spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[57]  Yuan-qing Xia,et al.  LC-FAIMS-MS/MS for quantification of a peptide in plasma and evaluation of FAIMS global selectivity from plasma components. , 2008, Analytical chemistry.

[58]  Darryl B. Hardie,et al.  A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. , 2010, Journal of proteome research.

[59]  Angus Nedderman,et al.  Analytical strategies for identifying drug metabolites. , 2007, Mass spectrometry reviews.